APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Anticoagulants

Anticoagulants, commonly referred to as blood thinners, are substances that prevent or reduce coagulation of blood, prolonging the clotting time. Some of them occur naturally in blood-eating animals such as leeches and mosquitoes, where they help keep the bite area unclotted long enough for the animal to obtain some blood. As a class of medications, anticoagulants are used in therapy for thrombotic disorders. Oral anticoagulants (OACs) are taken by many people in pill or tablet form, and various intravenous anticoagulant dosage forms are used in hospitals. Some anticoagulants are used in medical equipment, such as test tubes, serum-separating tubes, blood transfusion bags, and dialysis equipment.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Anticoagulants, commonly referred to as blood thinners, are substances that prevent or reduce coagulation of blood, prolonging the clotting time. Some of them occur naturally in blood-eating animals such as leeches and mosquitoes, where they help keep the bite area unclotted long enough for the animal to obtain some blood. As a class of medications, anticoagulants are used in therapy for thrombotic disorders. Oral anticoagulants (OACs) are taken by many people in pill or tablet form, and various intravenous anticoagulant dosage forms are used in hospitals. Some anticoagulants are used in medical equipment, such as test tubes, serum-separating tubes, blood transfusion bags, and dialysis equipment.

Selected research

Market Outlook & Growth Opportunities

Global Anticoagulants Market Outlook and Growth Opportunities 2026

2 January 2026192 pages

Choose your research edition.

Industry ResearchAnticoagulants Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Anticoagulants Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Anticoagulants Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anticoagulants Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Anticoagulants Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Anticoagulants, commonly referred to as blood thinners, are substances that prevent or reduce coagulation of blood, prolonging the clotting time. Some of them occur naturally in blood-eating animals such as leeches and mosquitoes, where they help keep the bite area unclotted long enough for the animal to obtain some blood. As a class of medications, anticoagulants are used in therapy for thrombotic disorders. Oral anticoagulants (OACs) are taken by many people in pill or tablet form, and various intravenous anticoagulant dosage forms are used in hospitals. Some anticoagulants are used in medical equipment, such as test tubes, serum-separating tubes, blood transfusion bags, and dialysis equipment.

Market competition is intense. Sanofi, Bristol-Myers Squibb, Bayer, Johnson & Johnson, Genentech (Roche) and Boehringer Ingelheim etc. are the leaders of the industry, with about 64% market shares.

North America is the largest consumption place, with a consumption market share nearly 39%. Following North America, Europe is the second largest consumption place with the consumption market share of 26%.

Read the full market overview

This report provides an overview of the global Anticoagulants market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anticoagulants and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anticoagulants revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Anticoagulants market.

Anticoagulants Segment by Company

Sanofi

Bristol-Myers Squibb

Bayer

Johnson & Johnson.

Genentech (Roche)

Boehringer Ingelheim

Lilly

Daiichi Sankyo

Otsuka

AstraZeneca

Pfizer

Aspen

The Medicines Company

Anticoagulants Segment by Type

Platelet Aggregation Inhibitors (PAI)

Low-Molecular-Weight Heparin (LMWH)

Direct Thrombin Inhibitor (DTI)

Direct Factor Xa Inhibitors (DFXa)

Vitamin K antagonists (VKA)

Others

Anticoagulants Segment by Application

VTE

ACS/MI

AF

Others

Anticoagulants Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Anticoagulants status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Anticoagulants key companies, revenue, market share, and recent developments.

3. To split the Anticoagulants breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Anticoagulants market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Anticoagulants significant trends, drivers, influence factors in global and regions.

6. To analyze Anticoagulants competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anticoagulants market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anticoagulants and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anticoagulants.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anticoagulants industry.

Chapter 3: Detailed analysis of Anticoagulants company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Anticoagulants in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Anticoagulants in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Anticoagulants Industry Trends Table 2. Anticoagulants Industry Drivers Table 3. Anticoagulants Industry Opportunities and Challenges Table 4. Anticoagulants Industry Restraints Table 5. Global Anticoagulants Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Anticoagulants Revenue Share by Company (2021-2026) Table 7. Global Anticoagulants Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Anticoagulants Key Company Manufacturing Base & Headquarters Table 9. Global Anticoagulants Company, Product Type & Application Table 10. Global Anticoagulants Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Anticoagulants by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Platelet Aggregation Inhibitors (PAI) Table 15. Significant Companies of Low-Molecular-Weight Heparin (LMWH) Table 16. Significant Companies of Direct Thrombin Inhibitor (DTI) Table 17. Significant Companies of Direct Factor Xa Inhibitors (DFXa) Table 18. Significant Companies of Vitamin K antagonists (VKA) Table 19. Significant Companies of Others Table 20. Global Anticoagulants Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 21. Global Anticoagulants Sales Value by Type (2021-2026) & (US$ Million) Table 22. Global Anticoagulants Sales Value by Type (2027-2032) & (US$ Million) Table 23. Global Anticoagulants Sales Value Share by Type (2021-2026) Table 24. Global Anticoagulants Sales Value Share by Type (2027-2032) Table 25. Significant Companies of VTE Table 26. Significant Companies of ACS/MI Table 27. Significant Companies of AF Table 28. Significant Companies of Others Table 29. Global Anticoagulants Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Anticoagulants Sales Value by Application (2021-2026) & (US$ Million) Table 31. Global Anticoagulants Sales Value by Application (2027-2032) & (US$ Million) Table 32. Global Anticoagulants Sales Value Share by Application (2021-2026) Table 33. Global Anticoagulants Sales Value Share by Application (2027-2032) Table 34. Global Anticoagulants Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Anticoagulants Sales Value by Region (2021-2026) & (US$ Million) Table 36. Global Anticoagulants Sales Value Share by Region (2021-2026) Table 37. Global Anticoagulants Sales Value by Region (2027-2032) & (US$ Million) Table 38. Global Anticoagulants Sales Value Share by Region (2027-2032) Table 39. Global Anticoagulants Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Anticoagulants Sales Value by Country (2021-2026) & (US$ Million) Table 41. Global Anticoagulants Sales Value Market Share by Country (2021-2026) Table 42. Global Anticoagulants Sales Value by Country (2027-2032) & (US$ Million) Table 43. Global Anticoagulants Sales Value Market Share by Country (2027-2032) Table 44. Sanofi Company Information Table 45. Sanofi Business Overview Table 46. Sanofi Anticoagulants Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Sanofi Anticoagulants Product Portfolio Table 48. Sanofi Recent Development Table 49. Bristol-Myers Squibb Company Information Table 50. Bristol-Myers Squibb Business Overview Table 51. Bristol-Myers Squibb Anticoagulants Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Bristol-Myers Squibb Anticoagulants Product Portfolio Table 53. Bristol-Myers Squibb Recent Development Table 54. Bayer Company Information Table 55. Bayer Business Overview Table 56. Bayer Anticoagulants Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Bayer Anticoagulants Product Portfolio Table 58. Bayer Recent Development Table 59. Johnson & Johnson. Company Information Table 60. Johnson & Johnson. Business Overview Table 61. Johnson & Johnson. Anticoagulants Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Johnson & Johnson. Anticoagulants Product Portfolio Table 63. Johnson & Johnson. Recent Development Table 64. Genentech (Roche) Company Information Table 65. Genentech (Roche) Business Overview Table 66. Genentech (Roche) Anticoagulants Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Genentech (Roche) Anticoagulants Product Portfolio Table 68. Genentech (Roche) Recent Development Table 69. Boehringer Ingelheim Company Information Table 70. Boehringer Ingelheim Business Overview Table 71. Boehringer Ingelheim Anticoagulants Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Boehringer Ingelheim Anticoagulants Product Portfolio Table 73. Boehringer Ingelheim Recent Development Table 74. Lilly Company Information Table 75. Lilly Business Overview Table 76. Lilly Anticoagulants Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Lilly Anticoagulants Product Portfolio Table 78. Lilly Recent Development Table 79. Daiichi Sankyo Company Information Table 80. Daiichi Sankyo Business Overview Table 81. Daiichi Sankyo Anticoagulants Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Daiichi Sankyo Anticoagulants Product Portfolio Table 83. Daiichi Sankyo Recent Development Table 84. Otsuka Company Information Table 85. Otsuka Business Overview Table 86. Otsuka Anticoagulants Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Otsuka Anticoagulants Product Portfolio Table 88. Otsuka Recent Development Table 89. AstraZeneca Company Information Table 90. AstraZeneca Business Overview Table 91. AstraZeneca Anticoagulants Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. AstraZeneca Anticoagulants Product Portfolio Table 93. AstraZeneca Recent Development Table 94. Pfizer Company Information Table 95. Pfizer Business Overview Table 96. Pfizer Anticoagulants Sales (kt), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 97. Pfizer Anticoagulants Product Portfolio Table 98. Pfizer Recent Development Table 99. Aspen Company Information Table 100. Aspen Business Overview Table 101. Aspen Anticoagulants Sales (kt), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 102. Aspen Anticoagulants Product Portfolio Table 103. Aspen Recent Development Table 104. The Medicines Company Company Information Table 105. The Medicines Company Business Overview Table 106. The Medicines Company Anticoagulants Sales (kt), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 107. The Medicines Company Anticoagulants Product Portfolio Table 108. The Medicines Company Recent Development Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. Anticoagulants Product Image Figure 2. Global Anticoagulants Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anticoagulants Market Size (2021-2032) & (US$ Million) Figure 4. Global Anticoagulants Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Platelet Aggregation Inhibitors (PAI) Image Figure 8. Low-Molecular-Weight Heparin (LMWH) Image Figure 9. Direct Thrombin Inhibitor (DTI) Image Figure 10. Direct Factor Xa Inhibitors (DFXa) Image Figure 11. Vitamin K antagonists (VKA) Image Figure 12. Others Image Figure 13. Global Anticoagulants Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 14. Global Anticoagulants Sales Value Share 2021 VS 2025 VS 2032 Figure 15. Global Anticoagulants Sales Value Share by Type (2021-2032) Figure 16. VTE Image Figure 17. ACS/MI Image Figure 18. AF Image Figure 19. Others Image Figure 20. Global Anticoagulants Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Anticoagulants Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Anticoagulants Sales Value Share by Application (2021-2032) Figure 23. Global Anticoagulants Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global Anticoagulants Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 25. North America Anticoagulants Sales Value (2021-2032) & (US$ Million) Figure 26. North America Anticoagulants Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Europe Anticoagulants Sales Value (2021-2032) & (US$ Million) Figure 28. Europe Anticoagulants Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Asia-Pacific Anticoagulants Sales Value (2021-2032) & (US$ Million) Figure 30. Asia-Pacific Anticoagulants Sales Value Share by Country (%), 2025 VS 2032 Figure 31. South America Anticoagulants Sales Value (2021-2032) & (US$ Million) Figure 32. South America Anticoagulants Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Middle East & Africa Anticoagulants Sales Value (2021-2032) & (US$ Million) Figure 34. Middle East & Africa Anticoagulants Sales Value Share by Country (%), 2025 VS 2032 Figure 35. USA Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. USA Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. USA Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Canada Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Canada Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Canada Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Mexico Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Mexico Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Mexico Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Germany Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Germany Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Germany Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. France Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. France Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. France Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. U.K. Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. U.K. Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. U.K. Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Italy Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Italy Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Italy Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Spain Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Spain Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Spain Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Russia Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Russia Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Russia Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Netherlands Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Netherlands Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Netherlands Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Nordic Countries Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Nordic Countries Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Nordic Countries Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. China Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. China Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. China Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Japan Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Japan Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Japan Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. South Korea Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. South Korea Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. South Korea Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. India Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. India Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. India Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Australia Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Australia Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Australia Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Southeast Asia Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Southeast Asia Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Southeast Asia Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Brazil Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Brazil Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Brazil Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Argentina Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Argentina Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Argentina Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Chile Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Chile Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Chile Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Colombia Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Colombia Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Colombia Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Peru Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Peru Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Peru Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Saudi Arabia Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Saudi Arabia Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Israel Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Israel Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Israel Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. UAE Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. UAE Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. UAE Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Turkey Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Turkey Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Turkey Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Iran Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Iran Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Iran Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Egypt Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Egypt Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Egypt Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Years Considered Figure 120. Research Process Figure 121. Key Executives Interviewed

Scope & coverage.

Types
  • Platelet Aggregation Inhibitors (PAI)
  • Low-Molecular-Weight Heparin (LMWH)
  • Direct Thrombin Inhibitor (DTI)
  • Direct Factor Xa Inhibitors (DFXa)
  • Vitamin K antagonists (VKA)
  • Others
Applications
  • VTE
  • ACS/MI
  • AF
  • Others
Companies covered
  • Sanofi
  • Bristol-Myers Squibb
  • Bayer
  • Johnson & Johnson.
  • Genentech (Roche)
  • Boehringer Ingelheim
  • Lilly
  • Daiichi Sankyo
  • Otsuka
  • AstraZeneca
  • Pfizer
  • Aspen
  • The Medicines Company

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Anticoagulants Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Anticoagulants Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Anticoagulants Market Dynamics
  1. 2.1 Anticoagulants Industry Trends
  2. 2.2 Anticoagulants Industry Drivers
  3. 2.3 Anticoagulants Industry Opportunities and Challenges
  4. 2.4 Anticoagulants Industry Restraints
3 Anticoagulants Market by Company
  1. 3.1 Global Anticoagulants Company Revenue Ranking in 2025
  2. 3.2 Global Anticoagulants Revenue by Company (2021-2026)
  3. 3.3 Global Anticoagulants Company Ranking (2024-2026)
  4. 3.4 Global Anticoagulants Company Manufacturing Base and Headquarters
  5. 3.5 Global Anticoagulants Company Product Type and Application
  6. 3.6 Global Anticoagulants Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Anticoagulants Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Anticoagulants Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Anticoagulants Market by Type
  1. 4.1 Anticoagulants Type Introduction
  2. 4.1.1 Platelet Aggregation Inhibitors (PAI)
  3. 4.1.2 Low-Molecular-Weight Heparin (LMWH)
  4. 4.1.3 Direct Thrombin Inhibitor (DTI)
  5. 4.1.4 Direct Factor Xa Inhibitors (DFXa)
  6. 4.1.5 Vitamin K antagonists (VKA)
  7. 4.1.6 Others
  8. 4.2 Global Anticoagulants Sales Value by Type
  9. 4.2.1 Global Anticoagulants Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Anticoagulants Sales Value by Type (2021-2032)
  11. 4.2.3 Global Anticoagulants Sales Value Share by Type (2021-2032)
5 Anticoagulants Market by Application
  1. 5.1 Anticoagulants Application Introduction
  2. 5.1.1 VTE
  3. 5.1.2 ACS/MI
  4. 5.1.3 AF
  5. 5.1.4 Others
  6. 5.2 Global Anticoagulants Sales Value by Application
  7. 5.2.1 Global Anticoagulants Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Anticoagulants Sales Value by Application (2021-2032)
  9. 5.2.3 Global Anticoagulants Sales Value Share by Application (2021-2032)
6 Anticoagulants Regional Value Analysis
  1. 6.1 Global Anticoagulants Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anticoagulants Sales Value by Region (2021-2032)
  3. 6.2.1 Global Anticoagulants Sales Value by Region: 2021-2026
  4. 6.2.2 Global Anticoagulants Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Anticoagulants Sales Value (2021-2032)
  7. 6.3.2 North America Anticoagulants Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Anticoagulants Sales Value (2021-2032)
  10. 6.4.2 Europe Anticoagulants Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Anticoagulants Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Anticoagulants Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Anticoagulants Sales Value (2021-2032)
  16. 6.6.2 South America Anticoagulants Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Anticoagulants Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Anticoagulants Sales Value Share by Country, 2025 VS 2032
7 Anticoagulants Country-level Value Analysis
  1. 7.1 Global Anticoagulants Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Anticoagulants Sales Value by Country (2021-2032)
  3. 7.2.1 Global Anticoagulants Sales Value by Country (2021-2026)
  4. 7.2.2 Global Anticoagulants Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Anticoagulants Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Anticoagulants Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Anticoagulants Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Anticoagulants Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Anticoagulants Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Anticoagulants Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Anticoagulants Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Anticoagulants Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Anticoagulants Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Anticoagulants Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Anticoagulants Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Anticoagulants Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Anticoagulants Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Anticoagulants Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Anticoagulants Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Anticoagulants Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Anticoagulants Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Anticoagulants Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Anticoagulants Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Anticoagulants Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Anticoagulants Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Anticoagulants Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Anticoagulants Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Anticoagulants Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Anticoagulants Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Anticoagulants Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Anticoagulants Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Anticoagulants Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Anticoagulants Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Anticoagulants Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Anticoagulants Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Anticoagulants Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Anticoagulants Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Anticoagulants Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Anticoagulants Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Anticoagulants Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Anticoagulants Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Anticoagulants Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Anticoagulants Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Anticoagulants Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Anticoagulants Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Anticoagulants Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Anticoagulants Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Anticoagulants Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Anticoagulants Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Anticoagulants Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Anticoagulants Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Anticoagulants Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Anticoagulants Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Anticoagulants Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Anticoagulants Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Anticoagulants Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Anticoagulants Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Anticoagulants Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Anticoagulants Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Anticoagulants Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Anticoagulants Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Anticoagulants Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Anticoagulants Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Anticoagulants Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Anticoagulants Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Anticoagulants Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Anticoagulants Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Anticoagulants Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Anticoagulants Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Anticoagulants Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Anticoagulants Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Anticoagulants Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Anticoagulants Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Anticoagulants Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Anticoagulants Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Anticoagulants Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Anticoagulants Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Anticoagulants Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Anticoagulants Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Anticoagulants Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Anticoagulants Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Anticoagulants Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Anticoagulants Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Anticoagulants Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Anticoagulants Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Anticoagulants Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Anticoagulants Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Anticoagulants Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Anticoagulants Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Anticoagulants Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Bristol-Myers Squibb
  8. 8.2.1 Bristol-Myers Squibb Company Information
  9. 8.2.2 Bristol-Myers Squibb Business Overview
  10. 8.2.3 Bristol-Myers Squibb Anticoagulants Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bristol-Myers Squibb Anticoagulants Product Portfolio
  12. 8.2.5 Bristol-Myers Squibb Recent Developments
  13. 8.3 Bayer
  14. 8.3.1 Bayer Company Information
  15. 8.3.2 Bayer Business Overview
  16. 8.3.3 Bayer Anticoagulants Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bayer Anticoagulants Product Portfolio
  18. 8.3.5 Bayer Recent Developments
  19. 8.4 Johnson & Johnson.
  20. 8.4.1 Johnson & Johnson. Company Information
  21. 8.4.2 Johnson & Johnson. Business Overview
  22. 8.4.3 Johnson & Johnson. Anticoagulants Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Johnson & Johnson. Anticoagulants Product Portfolio
  24. 8.4.5 Johnson & Johnson. Recent Developments
  25. 8.5 Genentech (Roche)
  26. 8.5.1 Genentech (Roche) Company Information
  27. 8.5.2 Genentech (Roche) Business Overview
  28. 8.5.3 Genentech (Roche) Anticoagulants Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Genentech (Roche) Anticoagulants Product Portfolio
  30. 8.5.5 Genentech (Roche) Recent Developments
  31. 8.6 Boehringer Ingelheim
  32. 8.6.1 Boehringer Ingelheim Company Information
  33. 8.6.2 Boehringer Ingelheim Business Overview
  34. 8.6.3 Boehringer Ingelheim Anticoagulants Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Boehringer Ingelheim Anticoagulants Product Portfolio
  36. 8.6.5 Boehringer Ingelheim Recent Developments
  37. 8.7 Lilly
  38. 8.7.1 Lilly Company Information
  39. 8.7.2 Lilly Business Overview
  40. 8.7.3 Lilly Anticoagulants Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Lilly Anticoagulants Product Portfolio
  42. 8.7.5 Lilly Recent Developments
  43. 8.8 Daiichi Sankyo
  44. 8.8.1 Daiichi Sankyo Company Information
  45. 8.8.2 Daiichi Sankyo Business Overview
  46. 8.8.3 Daiichi Sankyo Anticoagulants Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Daiichi Sankyo Anticoagulants Product Portfolio
  48. 8.8.5 Daiichi Sankyo Recent Developments
  49. 8.9 Otsuka
  50. 8.9.1 Otsuka Company Information
  51. 8.9.2 Otsuka Business Overview
  52. 8.9.3 Otsuka Anticoagulants Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Otsuka Anticoagulants Product Portfolio
  54. 8.9.5 Otsuka Recent Developments
  55. 8.10 AstraZeneca
  56. 8.10.1 AstraZeneca Company Information
  57. 8.10.2 AstraZeneca Business Overview
  58. 8.10.3 AstraZeneca Anticoagulants Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AstraZeneca Anticoagulants Product Portfolio
  60. 8.10.5 AstraZeneca Recent Developments
  61. 8.11 Pfizer
  62. 8.11.1 Pfizer Company Information
  63. 8.11.2 Pfizer Business Overview
  64. 8.11.3 Pfizer Anticoagulants Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Pfizer Anticoagulants Product Portfolio
  66. 8.11.5 Pfizer Recent Developments
  67. 8.12 Aspen
  68. 8.12.1 Aspen Company Information
  69. 8.12.2 Aspen Business Overview
  70. 8.12.3 Aspen Anticoagulants Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Aspen Anticoagulants Product Portfolio
  72. 8.12.5 Aspen Recent Developments
  73. 8.13 The Medicines Company
  74. 8.13.1 The Medicines Company Company Information
  75. 8.13.2 The Medicines Company Business Overview
  76. 8.13.3 The Medicines Company Anticoagulants Revenue and Gross Margin (2021-2026)
  77. 8.13.4 The Medicines Company Anticoagulants Product Portfolio
  78. 8.13.5 The Medicines Company Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst